Predictive Factors for Response to Peginterferon-Alpha and Ribavirin Treatment of Chronic HCV Infection in Patients Aged 65 Years and More

[1]  K. Hayashi,et al.  Efficacy of peginterferon‐α‐2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[2]  Ming‐Lung Yu,et al.  Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. , 2010, The Journal of infectious diseases.

[3]  A. Floreani.  Hepatitis C: Should antiviral therapy be offered to elderly patients? , 2009, Nature Reviews Gastroenterology &Hepatology.

[4]  J. Pawlotsky,et al.  Practical use of hepatitis C virus kinetics monitoring in the treatment of chronic hepatitis C , 2007, Journal of viral hepatitis.

[5]  M. Capobianchi,et al.  The Effect of Age on Response to Therapy With Peginterferon α Plus Ribavirin in a Cohort of Patients With Chronic HCV Hepatitis Including Subjects Older Than 65 Yr , 2007, The American Journal of Gastroenterology.

[6]  N. Hilzenrat,et al.  Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. , 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[7]  D. Thabut,et al.  Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease? , 2006, The American Journal of Gastroenterology.

[8]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[9]  A. Floreani,et al.  ARE ELDERLY PATIENTS POOR CANDIDATES FOR PEGYLATED INTERFERON PLUS RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C? , 2006, Journal of the American Geriatrics Society.

[10]  G. Davis,et al.  Projecting future complications of chronic hepatitis C in the United States , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  J. Hoofnagle,et al.  National institutes of health consensus development conference: Management of hepatitis C: 2002 , 2002, Clinics in liver disease.

[12]  G. Davis.  Monitoring of viral levels during therapy of hepatitis C , 2002, Hepatology.

[13]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[14]  A. Alberti,et al.  Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance , 2002, Gut.

[15]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[16]  M. Sawabe,et al.  Persistent infection of hepatitis C virus in the elderly: a clinical and quantitative pathological study of autopsy cases. , 1999, Liver.

[17]  R. Testa,et al.  Chronic liver disease related to hepatitis C virus: age of patients seems to be a determinant of severity independently of viral genotype. , 1999, European journal of gastroenterology & hepatology.

[18]  A. Mottola,et al.  Hepatitis C virus infection and related chronic liver disease in a resident elderly population: the Silea study , 1998, Journal of viral hepatitis.

[19]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[20]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[21]  M. Tong,et al.  Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.

[22]  S. Sauleda,et al.  The changing epidemiology of hepatitis C virus infection in Europe. , 2008, Journal of hepatology.

[23]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.

[24]  R. Esteban,et al.  Epidemiology of hepatitis C virus infection. , 1993, Journal of hepatology.